Clinical Trial Home Nursing Services Market Size, Share & Industry Analysis, By Service Type (Biological Sample Collection & Processing, Clinical Assessment & Safety Monitoring, Investigational Product Administration & Treatment Support, and Others), By Intervention Type (Small Molecules, Biologics, Medical Devices, and Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Area (Oncology, Infectious Diseases, Neurology, Cardiology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Medical Device Companies, CROs), and Regional Forecast, 2026-2034

The global clinical trial home nursing services market size was valued at USD 1.23 billion in 2025. The market is projected to grow from USD 1.35 billion in 2026 to USD 3.00 billion by 2034, exhibiting a CAGR of 10.5% during the forecast period.

Clinical trial home nursing services involve trained nurses performing protocol-driven clinical trial visits, procedures, and data collection directly inside a participant's home. The increasing number of clinical trials, increasing preference toward patient-centric clinical trial designs, and the expansion of hybrid decentralized trials are resulting in a growing adoption of these services in the market. The growing outsourcing of clinical trial activities among service providers is driving market expansion.

• For instance, according to 2026 data published by the National Center for Biotechnology Information (NCBI), approximately 599,324 clinical trials were registered globally.

Key players, including IQVIA and ICON plc, emphasize offering innovative services to strengthen their dominance in the market.

Clinical Trial Home Nursing Services Market Trends

Increasing Integration of Digital Health Technologies with Home Nursing Services is a Key Market Trend

The increasing incorporation of digital health solutions with home nursing services for clinical trials is emerging as a key trend in the global market. CROs, sponsors, and decentralized clinical trial service providers are increasingly combining in-person home nursing visits with digital technologies, including wearable and connected medical devices, remote patient monitoring, electronic patient-reported outcomes (ePRO), among others. Furthermore, digital technologies enable continuous or more frequent collection of participant data between physical nursing visits, further enhancing the provision of clinical home nursing services among the service providers.

• For instance, according to 2025 data from 1,097 decentralized clinical trials found that 1,008 trials (91.9%) used remote data collection, including patient-reported outcomes, wearables, and remote monitoring.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Increasing Adoption of Decentralized and Hybrid Clinical Trial Models to Boost Market Growth

The increasing number of clinical trials is enabling CROs, pharmaceutical and biotechnology companies, and clinical research organizations to integrate decentralized elements to shift selected trial services closer to individuals. Under these models, protocol-directed services including vital-sign measurement, biological sample collection and processing, safety assessments, and others are performed at participants' homes or other approved non-site locations by trained mobile healthcare professionals.

• For instance, according to 2026 data published by the National Center for Biotechnology Information (NCBI), it was reported that about 168,540 clinical trial studies were registered in the U.S.

Increasing healthcare expenditure, expansion of patient-centric models, and growing demand to enhance clinical trial efficiency and accessibility are driving the global clinical trial home nursing services market growth.

Market Restraints

Fragmented Regulatory Requirements for Home Trial Activities to Hamper Market Growth

The stringent and fragmented regulatory requirements for clinical trial activities conducted at participants' homes represent a key restraint on the global market. The home-based trials require service providers and sponsors to address additional requirements related to investigator oversight, informed consent, investigational product administration, adverse-event management, suitability of participants' homes for protocol-directed procedures, among others, which vary substantially between countries and jurisdictions.

In the U.S., the FDA requires sponsors to follow local laws and regulations, and licensing requirements for medical practice and investigational-product administration, noting that compliance may involve requirements across multiple U.S. states, territories, and other countries. Consequently, a clinical trial home nursing provider operating nationally may not be able to deploy the same nurse or operational model uniformly across every jurisdiction, thereby creating fragmentation in services offering further limiting market growth.

• For instance, according to 2025 data published by the National Center for Biotechnology Information (NCBI), the RADIAL decentralized clinical trial was implemented across six European countries and encountered differences in national legal and regulatory requirements despite operating under the EU Clinical Trials Regulation.

Market Opportunities

Expansion of Clinical Trials in Developing Countries to Create Major Market Opportunities

The expansion of clinical trials in emerging countries presents a key opportunity in the market. The clinical trial sponsors and service providers are shifting trial studies beyond conventional clinical trial facilities. Additionally, an increasing patient population, advancements in clinical research infrastructure, growing patient recruitment potential, and growing awareness of clinical trial home nursing services across developing countries, including China, Brazil, and others, are boosting the adoption of these services in the market. Furthermore, growing healthcare expenditure is boosting demand for clinical trial home nursing services in the market.

• According to 2025 data published by the International Trade Administration, healthcare expenditure was approximately USD 135.0 billion in Brazil.

Market Challenges

Limited Accessibility to Healthcare Facilities to Hinder Market Growth

There is an increasing demand for novel clinical trial home nursing services among the patient population. However, limited accessibility to healthcare facilities in emerging countries remains a major challenge in the global market. The lack of advanced clinical trial infrastructure and logistics networks, qualified clinical trial home nursing service providers, challenges in regulatory compliance, and a limited number of sponsors are resulting in a reduced number of registered clinical trials among companies and sponsors, thereby limiting market growth.

• For instance, according to 2025 data published by the World Health Organization (WHO), only 24,371 clinical trials were conducted in Belgium.

SEGMENTATION ANALYSIS

By Service Type

Increasing Utilization of Home Trial Services for Biological Sample Collection & Processing Led to Segmental Dominance

Based on service type, the market is classified into biological sample collection & processing, clinical assessment & safety monitoring, investigational product administration & treatment support, and others.

The biological sample collection & processing segment held the largest clinical trial home nursing services market share in 2025. The segment growth is driven by the growing adoption of recurring services, including sample collection services, resulting in a growing number of companies and sponsors providing innovative clinical trial home nursing services.

• For instance, according to data published by JAMA Network, an open study of Mayo Clinic’s decentralized clinical trial program covering 765 decentralized clinical trials and 7,469 accrued participants generated 224,370 clinical-trial phlebotomy orders, demonstrating the exceptionally high volume of blood-sampling requirements within clinical research programs. Of those 224,370 phlebotomy orders, 1,546 were collected remotely through the decentralized program.

The clinical assessment & safety monitoring segment is expected to grow at a CAGR of 10.8% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Investigational Intervention Type

Increasing Approval of Small Molecules Led to Segmental Dominance

By investigational intervention type, the market is divided into small molecules, biologics, medical devices, and others.

The small molecules segment dominated the global market in 2025, holding a share of 44.3%. The segment growth is mainly attributed to growing approvals and demand for small molecule therapies.

• According to the 2024 data published by the Cambridge Crystallographic Data Centre (CCDC), the FDA approved 34 new small molecule drugs in 2023 as compared to 21 in 2022.

The medical devices segment is set to flourish with a CAGR of 10.5% over the forecast period.

By Phase

Increasing Number of Phase III Clinical Trials Led to Dominance of Segment

In terms of phase, the market is divided into phase I, phase II, phase III, and phase IV.

The phase III segment dominated the global market with a 43.1% share in 2025. A growing number of registered phase III clinical trials is fueling segment growth. This, along with increasing funding initiatives by governmental organizations, is also contributing to the segmental growth.

• For instance, according to 2025 data published by the World Health Organization (WHO), approximately 10,754 phase III clinical trials were conducted in China.

The phase I segment is set to flourish with a CAGR of 10.1% over the forecast period.

By Therapeutic Area

Increasing Prevalence of Cancer Led to Oncology Segment Dominance

Based on therapeutic area, the market is divided into oncology, infectious diseases, neurology, cardiology, and others.

The oncology segment dominated the market in 2025. The increasing prevalence of various types of cancer, including prostate cancer and others, the growing demand for mobile clinical research nursing services, and the increasing number of companies offering these services are contributing to the segmental growth. Furthermore, the segment is set to hold a 31.8% share in 2026.

• For instance, according to 2026 data published by the National Cancer Institute (NCI), an estimated 2.1 million new cancer cases are projected to occur in the U.S.

Infectious diseases are projected to grow at a CAGR of 9.1% during the forecast period.

By End User

Growing Awareness about Off-site Clinical Trial Services Boosted Pharmaceutical & Biotechnological Companies Segment Growth

Based on end user, the market is divided into pharmaceutical & biotechnological companies, medical device companies, CROs, and others.

The pharmaceutical & biotechnological companies segment dominated the market in 2025. The increasing number of high-quality patient-centric clinical trials, growing awareness about off-site clinical trial services, and the increasing number of pharmaceutical and biotechnology companies are contributing to the segmental growth. Furthermore, the segment is set to hold a 50.7% share in 2026.

• For instance, according to 2026 data published by Cross River Therapy, there are about 5,000 pharmaceutical companies in the U.S.

CROs are projected to grow at a 11.3% CAGR during the forecast period.

Clinical Trial Home Nursing Services Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 0.48 billion, and also took the leading share in 2025 with USD 0.52 billion. The growing number of clinical trials, increasing adoption of digital solutions, and increasing number of contract research organizations are driving market expansion in the region.

• For instance, according to 2025 statistics published by the World Health Organization (WHO), about 22,683 phase III clinical trials were conducted in the U.S.

U.S. Clinical Trial Home Nursing Services Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 0.52 billion in 2026, accounting for roughly 38.6% of global sales.

Europe

Europe is projected to record a CAGR of 8.1% in the coming years, which is the second highest among all regions, and reach a valuation of USD 0.38 billion in 2026. The increasing prevalence of chronic conditions and adoption of clinical trial home nursing services is supporting market growth.

U.K. Clinical Trial Home Nursing Services Market

The U.K. market in 2026 is estimated at around USD 0.06 billion, representing roughly 4.3% of global revenues.

Germany Clinical Trial Home Nursing Services Market

The market in Germany is projected to reach approximately USD 0.06 billion in 2026, equivalent to around 4.8% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 0.28 billion in 2026 and secure the position of the third-largest region in the market. The increasing healthcare expenditure and growing demand for innovative clinical trial platforms are likely to support market growth in the coming years.

Japan Clinical Trial Home Nursing Services Market

The Japanese market in 2026 is estimated at around USD 0.05 billion, accounting for roughly 3.8% of global revenues.

China Clinical Trial Home Nursing Services Market

The market in China is projected to be one of the largest globally, with 2026 revenues estimated at around USD 0.08 billion, representing roughly 6.0% of global sales.

India Clinical Trial Home Nursing Services Market

The Indian market size in 2026 is estimated at around USD 0.04 billion, accounting for roughly 2.9% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 0.08 billion in 2026 due to the increasing home healthcare access and growing focus on long-term follow-up nursing models in the region. The Middle East & Africa market growth is driven by the growing number of key companies focusing on offering in-home clinical trial services. In the Middle East & Africa, the GCC is set to reach a valuation of USD 0.03 billion in 2026.

South Africa Clinical Trial Home Nursing Services Market

The South African market is projected to reach around USD 0.01 billion in 2026, representing roughly 0.9% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Key Companies’ Focus on Receiving GDPR Validation to Support Their Dominance

A strong services portfolio, coupled with a strong focus on inorganic growth strategies, is one of the key factors contributing to the dominance of these key market companies globally. IQVIA and ICON plc were major companies in the market in 2025. Furthermore, the growing focus of major companies on receiving GDPR validation to strengthen their presence.

For instance, in September 2020, IQVIA, a global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, announced its Decentralized Clinical Trial (DCT) program had received GDPR compliance validation from TRUSTArc.

Key players, including ICON plc and WEP Clinical, emphasize acquisitions and mergers among other companies to strengthen their presence in the market.

List of Key Clinical Trial Home Nursing Service Companies Profiled

• IQVIA (U.S.)
• ICON plc (Ireland)
• WEP Clinical (U.K.)
• FutureMeds (Poland)
• Parexel International (MA) Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Firma Clinical Research (U.S.)
• Lightship (U.S.)
• DCT Japan (Japan)
• HomeNurse4U (India)

KEY INDUSTRY DEVELOPMENTS

• February 2026: DCT Japan collaborated with Japan's National Cerebral and Cardiovascular Center, covering decentralized clinical trial execution and clinical-trial participant recruitment, including use of its satellite medical institution network.
• February 2026: Lightship, the modern clinical trial site organization, acquired Veda Trials, a company specializing in end-to-end clinical operations delivered in community care settings with an aim to increase its brand presence.
• January 2026: WEP Clinical, a full-service contract research organization (CRO), acquired Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies.
• September 2025: Parexel International (MA) Corporation, a global clinical research organization (CRO), partnered with Paradigm Health, a company rebuilding the clinical research ecosystem, to evolve how clinical trials are designed and conducted and accelerate the delivery of life-changing treatments to patients.
• September 2025: FutureMeds partnered with Gooseberry Research to expand home-based trial capabilities across the U.S. and Europe to increase its brand presence.

REPORT COVERAGE

The report provides a detailed global clinical trial home nursing services market analysis and focuses on key aspects such as leading companies and market segmentation, including service type, investigational intervention type, phase, therapeutic area, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1:      Revenues and Market Share of Major Clinical Trial Home Nursing Service Providers

• Collection of attributable home/mobile research nursing revenues from annual reports, investor presentations, company disclosures, service pages, case studies, and press releases.
• Analysis of major providers including IQVIA, MRN, PCM Trials/EmVenio, Illingworth Research Group, ICON/Accellacare, WEP Clinical, FutureMeds, Parexel, PPD/Thermo Fisher Scientific, Firma Clinical Research, Lightship, DCT Japan, HomeNurse4U, RP-CRO, Gooseberry Research, Fortrea, and other relevant providers.
• Isolation of clinical trial home/mobile nursing revenue from broader CRO, DCT technology, laboratory, logistics, patient-support, and general home-healthcare revenues.
• Inclusion of qualifying services delivered at participants’ homes or protocol-approved participant-preferred non-site locations, including workplaces, schools, temporary/care residences, and appropriate community locations.
• Estimation of provider revenues using disclosed home-visit volumes, trials supported, clinician networks, service mix, geography, visit complexity, and average revenue per visit.
• Inclusion of attributable program-management, nurse sourcing, credentialing, training, scheduling, documentation, travel-time, supplies/equipment handling, and quality-management fees.
• Adjustment for internally delivered home nursing by trial-site/hospital research staff to capture total economic value while preventing double counting.

Approach 2:   Participant, Home-Visit and Revenue-per-Visit Model

• Estimation of relevant interventional clinical trials and enrolled participants by country, phase, therapeutic area, and investigational intervention type.
• Identification of trials suitable for biological sample collection, clinical assessment, safety monitoring, investigational product administration, and other qualifying home/mobile nursing procedures.
• Estimation of home/mobile nursing penetration among eligible clinical trials.
• Calculation of participant utilization for protocol-mandated and optional home nursing programs.
• Estimation of screening, treatment-period, follow-up, repeat/rescue, and other billable home/mobile visits.
• Classification of visits according to service intensity and complexity, from routine sample collection to complex infusion and serial-PK visits.
• Application of country-specific revenue per visit, including nursing labor, billable travel, supplies, equipment, coordination, and provider margin.
• Core calculation:

Eligible Participants × Home-Nursing Penetration × Participant Utilization × Visits per Participant × Revenue per Visit

• Aggregation of country-level estimates into regional and global market values.

Approach 3:   Country-Level Clinical Trial Activity and Home-Nursing Demand Model

• Assessment of country-level interventional clinical trial volumes using ClinicalTrials.gov, CTIS, WHO ICTRP, and national clinical-trial registries.
• Analysis of trial mix by phase, therapeutic area, intervention type, sponsor type, enrollment, and study location.
• Evaluation of decentralized/hybrid trial adoption, participant travel burden, research-site density, geographic dispersion, and protocol complexity.
• Analysis of country-level availability and cost of GCP-trained nurses, phlebotomists, and other qualified mobile HCPs.
• Estimation of home/mobile nursing expenditure based on eligible trial activity, participant volumes, service utilization, visits per participant, and local service pricing.
• Adjustment for regulatory acceptance, nursing scope-of-practice rules, clinical research infrastructure, sponsor/CRO presence, and provider network coverage.
• Aggregation of country estimates to derive regional and global market size.

2. Top Down Approaches

Approach 1:  Analysis of Parent Market

• Assessment of the global clinical trial services / clinical development expenditure pool as the broader parent addressable market, using pharmaceutical and biotechnology clinical R&D spending, major CRO clinical-development revenues, sponsor disclosures, and institutional clinical-trial expenditure data.
• Isolation of the portion of parent-market expenditure attributable to patient-facing clinical trial execution, excluding discovery, preclinical research, regulatory consulting, data management, biostatistics, and other activities outside the scope of clinical trial home nursing.
• Estimation of the proportion of patient-facing trial expenditure involving decentralized, hybrid, or other off-site clinical trial activities, based on clinical-trial adoption trends, protocol analysis, regulatory developments, and sponsor/CRO disclosures.
• Estimation of the share of decentralized/off-site expenditure represented by in-person mobile healthcare-professional services, separating physical home/mobile visits from telehealth, eConsent, eCOA/ePRO, wearables, remote-monitoring platforms, and other technology-only services.
• Isolation of expenditure specifically attributable to clinical trial home/mobile nursing, including biological sample collection, clinical assessment and safety monitoring, investigational product administration, protocol-specific procedures, and other qualifying nursing activities.
• Inclusion of directly attributable provider-retained revenues for nurse/HCP travel time, scheduling, credentialing, training, visit documentation, clinical supplies/equipment management, quality oversight, and program coordination.
• Exclusion of laboratory testing, standalone courier/logistics charges, investigational drug/device value, patient reimbursements, standalone DCT platforms, telehealth-only services, and unrelated CRO revenues.
• Application of regional adjustments reflecting clinical-trial activity, decentralized-trial adoption, nursing labor costs, service pricing, regulatory acceptance, sponsor/CRO presence, and mobile-HCP availability.
• Comparison of the resulting top-down estimate with provider-revenue, participant/visit, active-trial, clinician-capacity, and country-level bottom-up models before final market triangulation.

3. List of Key Sources

• ClinicalTrials.gov
• WHO International Clinical Trials Registry Platform (ICTRP)
• EU Clinical Trials Information System (CTIS)
• ISRCTN Registry
• Japan Registry of Clinical Trials
• Chinese Clinical Trial Registry
• Clinical Trials Registry – India
• Australian New Zealand Clinical Trials Registry
• U.S. FDA
• European Medicines Agency / European Commission
• UK MHRA
• PMDA / MHLW, Japan
• NMPA, China
• CDSCO, India
• TGA, Australia
• Decentralized Trials & Research Alliance (DTRA)
• Association of Clinical Research Organizations (ACRO)
• Association of Clinical Research Professionals (ACRP)
• Society for Clinical Research Sites (SCRS)
• Drug Information Association (DIA)
• Company annual reports, investor presentations, official service pages, case studies, press releases, and financial disclosures
• Provider disclosures on home visits, trials supported, participants served, clinician-network size, and geographic coverage
• Government and academic nursing-wage/cost databases
• Clinical-trial protocols and peer-reviewed studies on decentralized and home-based trial implementation

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
• Clinical trial home/mobile nursing service providers
• Mobile research nursing operations heads
• CRO clinical operations executives
• Decentralized/hybrid trial program managers
• Clinical research nurse network managers
• Nurse recruitment, credentialing, and training managers
• Home-visit scheduling and patient-coordination teams
• Business development and commercial executives
• Clinical supply and investigational-product coordination managers
• Clinical quality assurance and regulatory professionals
• Site-network and decentralized-trial operations executives
• Demand Side Interviews: 40%
• Key respondents:
• Pharmaceutical & biotechnology clinical development executives
• Medical device clinical affairs executives
• Clinical trial outsourcing/procurement managers
• Sponsor study managers and clinical operations directors
• CRO project managers
• Principal investigators and clinical research site directors
• Research nurses and study coordinators
• Decentralized clinical trial strategy leads
• Patient engagement and retention specialists
• Clinical trial reimbursement and contracting specialists
• Regulatory and GCP experts